[A16-32] Elotuzumab - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2016
Project no.:
A16-32
Commission:
Commission awarded on 01.06.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-80 | Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-66 | Elotuzumab (multiple myeloma) - Addendum to Commission A16-32 | Commission completed |
| A21-90 | Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2016-12-01 A G-BA decision was published.